These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12172398)

  • 21. Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy.
    Nemeth A; Szakmary K; Kramer J; Dinya E; Pados G; Fust G; Huettinger M
    Eur J Clin Chem Clin Biochem; 1995 Nov; 33(11):799-804. PubMed ID: 8620056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator activated receptor-gamma, leptin and tumor necrosis factor-alpha mRNA expression during very low calorie diet in subcutaneous adipose tissue in obese women.
    Bastard JP; Hainque B; Dusserre E; Bruckert E; Robin D; Vallier P; Perche S; Robin P; Turpin G; Jardel C; Laville M; Forest C; Vidal H
    Diabetes Metab Res Rev; 1999; 15(2):92-8. PubMed ID: 10362456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
    N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.
    Miller M; Bachorik PS; McCrindle BW; Kwiterovich PO
    Am J Med; 1993 Jan; 94(1):7-12. PubMed ID: 8420303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of gemfibrozil therapy for raising high density lipoprotein levels.
    Weis S; Kudchodkar BJ; Clearfield MB; Lacko AG
    Artery; 1992; 19(6):353-66. PubMed ID: 1471924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC; Duriez P
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.
    Brouillette C; Bossé Y; Pérusse L; Gaudet D; Vohl MC
    J Hum Genet; 2004; 49(8):424-432. PubMed ID: 15249972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
    Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
    Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia.
    Vohl MC; Lepage P; Gaudet D; Brewer CG; Bétard C; Perron P; Houde G; Cellier C; Faith JM; Després JP; Morgan K; Hudson TJ
    J Lipid Res; 2000 Jun; 41(6):945-52. PubMed ID: 10828087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation.
    Lindi V; Schwab U; Louheranta A; Laakso M; Vessby B; Hermansen K; Storlien L; Riccardi G; A Rivellese A;
    Mol Genet Metab; 2003 May; 79(1):52-60. PubMed ID: 12765846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.
    Avellone G; Di Garbo V; Cordova R; Piliego T; Raneli G; De Simone R; Bompiani GD
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):543-8. PubMed ID: 7578896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy.
    Lacko AG; Kudchodkar BJ; Loney WW; Clearfield MB; Weis S
    Clin Chem Lab Med; 1998 Jun; 36(6):389-92. PubMed ID: 9711427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of gemfibrozil therapy: predictive response from lipoprotein subfraction analysis.
    Loney WW; Kudchodkar BJ; Weis S; Clearfield MB; Shores J; Lacko AG
    Am J Ther; 1997; 4(9-10):301-9. PubMed ID: 10423623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoproteins and coronary heart disease in the Helsinki Heart Study.
    Mänttäri M; Huttunen JK; Koskinen P; Manninen V; Tenkanen L; Heinonen OP; Frick MH
    Eur Heart J; 1990 Dec; 11 Suppl H():26-31. PubMed ID: 2073911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
    Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans.
    Meirhaeghe A; Fajas L; Helbecque N; Cottel D; Lebel P; Dallongeville J; Deeb S; Auwerx J; Amouyel P
    Hum Mol Genet; 1998 Mar; 7(3):435-40. PubMed ID: 9467001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity.
    Kahri J; Vuorinen-Markkola H; Tilly-Kiesi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1993 Aug; 102(1):79-89. PubMed ID: 8257455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Asztalos BF; Collins D; Horvath KV; Bloomfield HE; Robins SJ; Schaefer EJ
    Metabolism; 2008 Jan; 57(1):77-83. PubMed ID: 18078862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease.
    Brune S; Kölsch H; Ptok U; Majores M; Schulz A; Schlosser R; Rao ML; Maier W; Heun R
    J Neural Transm (Vienna); 2003 Sep; 110(9):1041-50. PubMed ID: 12938026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.